Profile data is unavailable for this security.
About the company
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
- Revenue in USD (TTM)301.87m
- Net income in USD-59.29m
- Incorporated2010
- Employees249.00
- LocationCoherus BioSciences IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 649-3530
- Fax+1 (302) 655-5049
- Websitehttps://www.coherus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -37.37m | 179.73m | 42.00 | -- | 29.65 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Zevra Therapeutics Inc | 28.01m | -50.90m | 182.48m | 65.00 | -- | 3.74 | -- | 6.52 | -1.34 | -1.34 | 0.7513 | 1.17 | 0.2172 | -- | 3.47 | 430,876.90 | -39.48 | -32.11 | -47.94 | -39.89 | 51.11 | -- | -181.75 | -128.42 | -- | -- | 0.4683 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Generation Bio Co | 9.96m | -169.06m | 182.95m | 174.00 | -- | 1.39 | -- | 18.36 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Q32 Bio Inc | 354.00k | -83.09m | 184.98m | 39.00 | -- | 3.79 | -- | 522.55 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Abeona Therapeutics Inc | 3.50m | -76.66m | 188.63m | 84.00 | -- | -- | -- | 53.89 | -3.20 | -3.20 | 0.1461 | -0.3224 | 0.0546 | -- | 2.54 | 41,666.67 | -119.62 | -53.22 | -140.83 | -65.81 | -- | -- | -2,190.26 | -1,894.25 | -- | -- | 1.97 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Biomea Fusion Inc | 0.00 | -127.27m | 189.07m | 110.00 | -- | 1.40 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 190.17m | 25.00 | -- | 2.57 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 190.73m | 167.00 | -- | -- | -- | 1.02 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -58.67m | 190.95m | 57.00 | -- | 0.7084 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 191.23m | 274.00 | -- | 0.9218 | -- | 2.69 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 191.59m | 249.00 | -- | -- | -- | 0.6347 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Pyxis Oncology Inc | 16.15m | -57.80m | 198.45m | 51.00 | -- | 1.08 | -- | 12.29 | -1.39 | -1.39 | 0.368 | 3.13 | 0.0801 | -- | -- | 322,920.00 | -28.68 | -- | -30.64 | -- | 97.06 | -- | -358.00 | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Rezolute Inc | 0.00 | -58.21m | 202.96m | 51.00 | -- | 2.24 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 204.10m | 58.00 | -- | 1.39 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Data as of Jun 21 2024. Currency figures normalised to Coherus BioSciences Inc's reporting currency: US Dollar USD
42.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rubric Capital Management LPas of 31 Mar 2024 | 10.40m | 9.07% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.90m | 8.63% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.80m | 7.67% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 20 May 2024 | 6.22m | 5.42% |
| Citadel Advisors LLCas of 31 Mar 2024 | 2.63m | 2.29% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.63m | 2.29% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.20m | 1.92% |
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 2.05m | 1.79% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.00m | 1.74% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Mar 2024 | 1.93m | 1.68% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
